Pacer Advisors Portfolio holdings
AUM
$39.6B
1-Year Return
5.04%
This Quarter Return
-4.31%
1 Year Return
+5.04%
3 Year Return
+42.86%
5 Year Return
+91.64%
10 Year Return
+332.32%
AUM
$43.7B
AUM Growth
+$158M
(+0.36%)
Cap. Flow
+$1.17B
Cap. Flow
% of AUM
2.67%
Top 10 Holdings %
Top 10 Hldgs %
11.64%
Holding
4,109
New
199
Increased
895
Reduced
1,260
Closed
190
Top Buys
| 1 |
Hewlett Packard
HPE
|
$488M |
| 2 |
Halliburton
HAL
|
$458M |
| 3 |
Archer Daniels Midland
ADM
|
$456M |
| 4 |
Gen Digital
GEN
|
$413M |
| 5 |
WESCO International
WCC
|
$251M |
Top Sells
| 1 |
Vistra
VST
|
$614M |
| 2 |
Exxon Mobil
XOM
|
$498M |
| 3 |
Chevron
CVX
|
$435M |
| 4 |
Occidental Petroleum
OXY
|
$432M |
| 5 |
Cisco
CSCO
|
$411M |
Sector Composition
| 1 | Consumer Discretionary | 17.28% |
| 2 | Technology | 17.14% |
| 3 | Energy | 14.05% |
| 4 | Industrials | 10.98% |
| 5 | Healthcare | 9.59% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
INFN
1326
DELISTED
Infinera Corporation Common Stock
INFN
| $18.1K | ﹤0.01% |
2,977
-664
| -18% | -$4.04K |
|
1327
ADMA Biologics
ADMA
$4.03B
| $17.8K | ﹤0.01% |
1,592
-1,582
| -50% | -$17.7K |
|
1328
PTC Therapeutics
PTCT
$4.55B
| $17.5K | ﹤0.01% |
571
-796
| -58% | -$24.3K |
|
1329
Vericel Corp
VCEL
$1.72B
| $17.3K | ﹤0.01% |
376
-429
| -53% | -$19.7K |
|
1330
Recursion Pharmaceuticals
RXRX
$2.01B
| $17K | ﹤0.01% |
2,263
-1,549
| -41% | -$11.6K |
|
1331
Rhythm Pharmaceuticals
RYTM
$6.78B
| $17K | ﹤0.01% |
413
-605
| -59% | -$24.8K |
|
1332
Apogee Therapeutics
APGE
$2.26B
| $16.8K | ﹤0.01% |
426
+116
| +37% | +$4.57K |
|
1333
NETSCOUT
NTCT
$1.79B
| $16.7K | ﹤0.01% |
914
-224
| -20% | -$4.1K |
|
1334
BioCryst Pharmaceuticals
BCRX
$1.74B
| $16.4K | ﹤0.01% |
2,649
-4,657
| -64% | -$28.8K |
|
1335
Nurix Therapeutics
NRIX
$758M
| $16.3K | ﹤0.01% |
781
-204
| -21% | -$4.26K |
|
1336
Akero Therapeutics
AKRO
$3.58B
| $16.1K | ﹤0.01% |
688
-677
| -50% | -$15.9K |
|
1337
ImmunityBio
IBRX
$2.27B
| $15.7K | ﹤0.01% |
2,478
-3,619
| -59% | -$22.9K |
|
1338
Kymera Therapeutics
KYMR
$3.11B
| $15.4K | ﹤0.01% |
517
-464
| -47% | -$13.9K |
|
1339
Keros Therapeutics
KROS
$633M
| $14.9K | ﹤0.01% |
327
-233
| -42% | -$10.6K |
|
1340
Protagonist Therapeutics
PTGX
$3.77B
| $14.8K | ﹤0.01% |
428
-685
| -62% | -$23.7K |
|
1341
Kura Oncology
KURA
$713M
| $14.6K | ﹤0.01% |
709
-742
| -51% | -$15.3K |
|
|
SMAR
1342
DELISTED
Smartsheet Inc.
SMAR
| $14.5K | ﹤0.01% |
328
-711
| -68% | -$31.3K |
|
|
MORF
1343
DELISTED
Morphic Holding, Inc. Common Stock
MORF
| $14.4K | ﹤0.01% |
424
-606
| -59% | -$20.6K |
|
1344
Rocket Pharmaceuticals
RCKT
$354M
| $14.4K | ﹤0.01% |
669
-859
| -56% | -$18.5K |
|
1345
Arcutis Biotherapeutics
ARQT
$2.06B
| $13.7K | ﹤0.01% |
1,476
-2,399
| -62% | -$22.3K |
|
1346
Veracyte
VCYT
$2.55B
| $13.6K | ﹤0.01% |
626
-811
| -56% | -$17.6K |
|
1347
Mirum Pharmaceuticals
MIRM
$3.82B
| $13.4K | ﹤0.01% |
392
-848
| -68% | -$29K |
|
1348
Myriad Genetics
MYGN
$615M
| $13K | ﹤0.01% |
532
-628
| -54% | -$15.4K |
|
1349
Sportradar
SRAD
$9.14B
| $12.7K | ﹤0.01% |
1,138
-24
| -2% | -$268 |
|
1350
Soleno Therapeutics
SLNO
$3.71B
| $12.5K | ﹤0.01% |
307
-184
| -37% | -$7.51K |
|